S&P Futures
3,863.75 +15.50 (+0.40%) Dow Futures
31,135.00 +122.00 (+0.39%) Nasdaq Futures
11,941.00 +60.75 (+0.51%) Russell 2000 Futures
1,737.70 +9.10 (+0.53%) Crude Oil
98.41 -0.12 (-0.12%) Gold
1,740.80 +4.30 (+0.25%)
Northwest Biotherapeutics, Inc. (NWBO)
Chart Events
Performance Outlook
| Previous Close | 0.7253 |
| Open | 0.7256 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.6725 - 0.7977 |
| 52 Week Range | 0.3900 - 2.0500 |
| Volume | |
| Avg. Volume | 4,610,153 |
| Market Cap | 752.949M |
| Beta (5Y Monthly) | 0.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0630 |
| Earnings Date | May 10, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NWBO
Related Research
- NORTHWEST BIOTHERAPEUTICS INCTechnical Assessment: Bearish in the Intermediate-TermMarket sentiment remains in the tank and the stock market simply cannot put together a decent rally. The National Association of Active Investment Managers (NAAIM) exposure index has fallen back to 20%, an extremely low equity exposure and a very bearish stance toward equities. This is the second time the index has dropped to 20% in the past six weeks. The seven-week average of exposure has fallen to 30%, the lowest since the pandemic low, as well as in 2015, 2011, and 2008/2009.RatingFair ValueEconomic Moat7 days agoArgus Research
- PR Newswire
Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that an application for license of the manufacturing facility in Sawston, UK for commercial manufacturing of cellular therapies has been submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA). The application builds upon the 3 licenses received for the Sawston facility in 2021.
- PR Newswire
Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that yesterday on June 4, 2022, in the Industry Expert Theater during the ASCO 2022 conference, Dr. Marnix Bosch made a presentation discussing the Company's DCVax-L technology for personalized dendritic cell vaccines, the Sawston, UK facility, the manufacturing technology, the development of automation, and preparations for manufacturing s
- PR Newswire
Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that, as previously announced, a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma" will be made today at 11:10 a.m., at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences. The presentation will be made by Dr. Paul Mulholland of University College Hospital.
